Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for United Therapeutics (UTHR) over the last 11 years, with Q3 2025 value amounting to $44.6 million.

  • United Therapeutics' Shares Outstanding (Weighted Average) fell 154.53% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.6 million, marking a year-over-year decrease of 154.53%. This contributed to the annual value of $45.2 million for FY2024, which is 341.88% down from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Shares Outstanding (Weighted Average) is $44.6 million, which was down 154.53% from $45.1 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $47.0 million in Q1 2024 and a low of $44.6 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $45.3 million (2024), whereas its average is $45.6 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 330.4% in 2023, then plummeted by 446.81% in 2025.
  • Quarter analysis of 5 years shows United Therapeutics' Shares Outstanding (Weighted Average) stood at $44.9 million in 2021, then rose by 1.34% to $45.5 million in 2022, then rose by 2.86% to $46.8 million in 2023, then decreased by 3.42% to $45.2 million in 2024, then fell by 1.33% to $44.6 million in 2025.
  • Its last three reported values are $44.6 million in Q3 2025, $45.1 million for Q2 2025, and $44.9 million during Q1 2025.